Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Rodeo Therapeutics

- PMLiVE

Amgen’s Uplizna shows promise in rare fibroinflammatory disease IgG4-RD

The company is planning to file for US approval of the CD19-targeted drug in this patient population

- PMLiVE

Amgen’s interchangeable Soliris biosimilar Bkemv approved by FDA for rare blood disorders

Bkemv has been authorised to treat paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome

- PMLiVE

Amgen’s Imdelltra granted FDA accelerated approval to treat small cell lung cancer

More than 234,000 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti

The biosimilars have been authorised for all indications covered by Amgen's reference medicines

- PMLiVE

UK Biobank reveals new data from world’s largest genetic project

The data will accelerate the development of potentially lifesaving treatments and cures

- PMLiVE

Amgen’s Wezlana receives FDA approval to treat multiple inflammatory diseases

Wezlana is approved as a biosimilar referencing Janssen Pharmaceuticals’ Stelara

- PMLiVE

Amgen presents new findings for Uplizna in neuromyelitis optica spectrum disorder

The rare and debilitating disease affects approximately one to ten per 100,000 people

- PMLiVE

World Atopic Eczema Day 2023: Almirall unveils awareness campaign

The inflammatory skin disease is estimated to affect 4.4% of adults in the EU

- PMLiVE

Amgen free to proceed with $27.8bn Horizon acquisition following US FTC settlement

The FTC filed an antitrust lawsuit against Amgen earlier this year in a bid to block the transaction

- PMLiVE

Alliance for Genomic Discovery announces its five founding biopharma members

The AGD aims to accelerate drug development and expand the diversity of genomic data

- PMLiVE

Amgen’s supplemental Biologics License Application for Blincyto approved by FDA

The approval for the leukaemia drug was supported by additional data from two phase 3 studies

- PMLiVE

Amgen’s Lumakras shows promise in phase 3 lung cancer study

The company has also presented results from a study of Lumakras in colorectal cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links